The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2022 | HIMALAYA: tremelimumab + durvalumab in unresectable HCC
Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of HIMALAYA, (NCT03298451), an open-label, randomized, multicenter, Phase III study evaluating single dose tremelimumab plus regular intervals of durvalumab versus standard of care (SOC) sorafenib (STRIDE regimen) in patients with unresectable hepatocellular carcinoma. In conclusion, the results show the STRIDE regimen is a notably improved treatment option for patients with uHCC, both in terms of efficacy and safety and therefore a promising new first-line SOC for this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
